- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06336356
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
March 22, 2024 updated by: AstraZeneca
A Randomised, Double-blind, Placebo-controlled Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone Stimulation Test Following Treatment With Baxdrostat for 8 Weeks in Participants With Uncontrolled Hypertension
The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a placebo-controlled study to evaluate cortisol reserve after ACTH stimulation test following treatment with 2 milligrams (mg) baxdrostat versus placebo.
The study consists of 3 period:
- 4-week screening period.
- An 8-week double-blind treatment period.
- A safety follow-up 2 weeks after last dose.
Participants will be randomized in a 2:1 ratio to one of 2 treatment arms:
- Baxdrostat
- Placebo
Participants will receive either baxdrostat or placebo.
The overall study duration will be up to 16 weeks.
Study Type
Interventional
Enrollment (Estimated)
45
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants with mean seated systolic blood pressure (SBP) on automated office blood pressure measurement (AOBPM) greater than equal to (>=) 130 millimeter of mercury (mmHg) and less than (<) 170 mmHg at screening.
- Participants with mean seated SBP on AOBPM of >=130 mmHg and < 170 mmHg at randomization.
- Participants must have a stable regimen of >=1 antihypertensive medication (at least one should be a diuretic), for at least 4 weeks prior to screening.
- Participants must have an estimated glomerular filtration rate (eGFR) >=45 milliliter per minute (mL/min)/1.73-meter square (m^²) at screening.
- Participants must have a serum potassium+ (K+) level >=3.5 and < 5.0 millimole per liter (mmol/L) at screening.
Exclusion Criteria:
- Mean seated diastolic blood pressure (DBP) on AOBPM >=110 mmHg at randomization.
- Prior treatment (within the 4 weeks before screening) with angiotensin receptor Blocker (ARBs) and angiotensin converting enzyme inhibitor (ACEIs) (both taken simultaneously).
- Serum sodium (Na+) level < 135 millimole per liter (mmol/L) at screening, determined as per central laboratory.
- New York heart association functional heart failure (HF) Class IV at screening.
- Planned percutaneous coronary intervention/coronary artery bypass grafting or percutaneous coronary intervention/coronary artery bypass grafting done within 6 months prior to screening.
- Uncontrolled diabetes with glycated haemoglobin (HbA1c) > 10.0% (86 mmol/mol) at screening.
- Fridericia's corrected QT (QTcF) value > 470 milliseconds (ms) at screening, unless having a pacemaker.
- Heart rate < 45 or > 110 beats/min in a resting position, as per vital signs assessment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: Baxdrostat 2 mg
Participants will receive baxdrostat 2 mg tablet orally once daily.
|
Baxdrostat will be administered orally once daily.
Other Names:
|
Placebo Comparator: Arm 2: Placebo
Participants will receive placebo tablet orally once daily.
|
Placebo will be administered orally once daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Individual Cortisol Level
Time Frame: At baseline and Week 8
|
The serum free cortisol response before and after ACTH stimulation test will be evaluated.
|
At baseline and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Abnormal Stimulated Cortisol
Time Frame: At Week 8
|
Total serum cortisol response after ACTH stimulation test at Week 8 will be evaluated.
|
At Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 13, 2024
Primary Completion (Estimated)
November 5, 2024
Study Completion (Estimated)
November 5, 2024
Study Registration Dates
First Submitted
March 22, 2024
First Submitted That Met QC Criteria
March 22, 2024
First Posted (Actual)
March 28, 2024
Study Record Updates
Last Update Posted (Actual)
March 28, 2024
Last Update Submitted That Met QC Criteria
March 22, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D6970C00011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org.
All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",
indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles.
For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncontrolled Hypertension
-
CVRx, Inc.Suspended
-
Verve Medical, IncClinical Accelerator (CRO); Israeli-Georgian Medical Research Clinic Helsicore and other collaboratorsActive, not recruitingHypertension | Uncontrolled HypertensionGeorgia
-
Abbott Medical DevicesCompletedUncontrolled HypertensionSpain, Belgium, Estonia, Italy, Portugal, United Kingdom
-
Medtronic VascularCompletedUncontrolled HypertensionUnited States
-
Medtronic VascularCompletedUncontrolled HypertensionAustralia, New Zealand
-
Ottawa Hospital Research InstituteThe Ottawa Hospital Academic Medical AssociationTerminatedUncontrolled HypertensionCanada
-
Lepu Medical Technology (Beijing) Co., Ltd.Recruiting
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionArgentina, China, Korea, Republic of, Vietnam, Japan, Philippines, Hong Kong, Turkey, India, Australia, Russian Federation
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionUnited States, Canada, Italy, South Africa, Korea, Republic of, Australia, Belgium, France, Germany, Poland, Japan, Spain, Vietnam, Argentina, Bulgaria, Turkey, India, Malaysia, Taiwan, Thailand, Austria, Israel, Netherlands, Sweden, United... and more
-
Oslo University HospitalUniversity of Oslo; University Hospital of North Norway; Haukeland University... and other collaboratorsActive, not recruitingUncontrolled HypertensionNorway
Clinical Trials on Baxdrostat
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompleted
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionArgentina, China, Korea, Republic of, Vietnam, Japan, Philippines, Hong Kong, Turkey, India, Australia, Russian Federation
-
AstraZenecaRecruitingResistant HypertensionSpain, Argentina, United States, Belgium, Czechia, Vietnam, Thailand, Australia, Turkey, Philippines, Greece, Taiwan, United Kingdom, Poland, South Africa, Canada, Germany, Hungary, Malaysia, Bulgaria, Saudi Arabia, Slovakia
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionUnited States, Canada, Italy, South Africa, Korea, Republic of, Australia, Belgium, France, Germany, Poland, Japan, Spain, Vietnam, Argentina, Bulgaria, Turkey, India, Malaysia, Taiwan, Thailand, Austria, Israel, Netherlands, Sweden, United... and more
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompletedStudy to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal FunctionHypertensionUnited States
-
CinCor Pharma, Inc.CompletedResistant HypertensionUnited States
-
AstraZenecaCompleted